Intest Res > Volume 18(2); 2020 > Article |
|
FINANCIAL SUPPORT
This work was supported by the National Natural Science Foundation of China (NSFC grant Nos. 81470821, 81270473, 81670607, and 81970483).
CONFLICT OF INTEREST
Chen M has received speaker fees from Janssen, Falk, Takeda, and Ipson. He Y has received speaker fees from Janssen, Falk, and Ipson. Ben-Horin S has received consultancy fees and/or research support from AbbVie, Schering-Plough, Janssen, Celltrion, and Takeda. No other potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION
Conceptualization: Chen M, Zhao Y, Chen B, He Y. Methodology: Zhao Y. Formal analysis: Zhao Y. Funding acquisition: Chen M, Zhang S, Mao R. Project administration: Qiu Y, Feng R, Yang H. Visualization: Zeng Z. Writing - original draft: Zhao Y, Mao R. Writing: Mao R, Ben-Horin S. Approval of final manuscript: all authors.
Characteristic |
AMH |
Univariable analysis |
Multivariable analysis |
|||
---|---|---|---|---|---|---|
≤2 ng/mL (n=38) | >2 ng/mL (n=49) | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Age (yr) | ||||||
≤ 25 | 6 | 24 | Reference | |||
> 25 | 32 | 25 | 5.12 (1.82-14.42) | 0.002 | 10.03 (1.90-52.93) | 0.007 |
Duration (yr) | ||||||
≤ 6 | 15 | 26 | Reference | |||
> 6 | 23 | 23 | 2.64 (1.10-6.32) | 0.029 | ||
IBD related surgery historya | ||||||
Yes | 8 | 5 | 2.35 (0.70-7.87) | 0.167 | ||
No | 30 | 44 | Reference | |||
Disease behavior | ||||||
B1 | 23 | 39 | Reference | |||
B2 | 11 | 5 | 3.70 (1.15-12.09) | 0.028 | ||
B3 | 4 | 5 | 1.36 (0.33-5.57) | 0.672 | ||
Perianal disease | ||||||
Yes | 15 | 8 | 3.34 (1.23-9.07) | 0.018 | ||
No | 23 | 41 | Reference | |||
Disease activity | ||||||
In remission | 7 | 37 | Reference | |||
Active disease | 31 | 12 | 13.65 (4.79-38.91) | < 0.001 | 27.99 (6.13-127.95) | < 0.001 |
Location | ||||||
L1 | 9 | 15 | Reference | |||
L2 | 7 | 16 | 0.73 (0.22-2.45) | 0.610 | ||
L3 | 22 | 18 | 2.04 (0.74-5.73) | 0.178 | ||
Upper GI locationb | ||||||
Yes | 7 | 4 | 2.54 (0.69-9.42) | 0.163 | ||
No | 31 | 45 | Reference | |||
Medication history | ||||||
5-ASA/no treatment | 6 | 12 | Reference | |||
Steroid/infliximab | 3 | 6 | 1.00 (0.18-5.46) | 0.999 | ||
AZA | 12 | 27 | 0.89 (0.27-2.93) | 0.847 | ||
Thalidomide | 17 | 4 | 8.50 (1.96-36.79) | 0.004 | 15.66 (2.22-110.65) | 0.006 |
a Defined as any surgery that comprised of a diversion, stricturoplasty, and luminal resection, anytime during the follow-up period. Perianal abscess drainage or seton placement were not included.
Characteristic |
AMH |
Univariable analysis |
Multivariable analysis |
|||
---|---|---|---|---|---|---|
≤1.1 ng/mL (n=30) | >1.1 ng/mL (n=57) | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Age (yr) | ||||||
≤ 25 | 4 | 26 | Reference | |||
> 25 | 26 | 31 | 5.45 (1.68-17.65) | 0.005 | 15.28 (2.08-112.08) | 0.007 |
Duration (yr) | ||||||
≤ 6 | 13 | 33 | Reference | |||
> 6 | 17 | 24 | 1.79 (0.73-4.39) | 0.198 | ||
IBD related surgery historya | ||||||
Yes | 8 | 5 | 3.38 (1.11-12.86) | 0.033 | ||
No | 22 | 52 | Reference | |||
Disease behavior | ||||||
B1 | 17 | 45 | Reference | |||
B2 | 9 | 7 | 3.40 (1.10-10.58) | 0.034 | ||
B3 | 4 | 5 | 2.12 (0.58-8.83) | 0.303 | ||
Perianal disease | ||||||
Yes | 12 | 11 | 2.79 (1.04-7.45) | 0.041 | ||
No | 18 | 46 | Reference | |||
Disease activity | ||||||
In remission | 5 | 39 | Reference | |||
Active disease | 25 | 18 | 10.83 (3.57-32.90) | < 0.001 | 36.27 (4.69-147.23) | < 0.001 |
Location | ||||||
L1 | 7 | 17 | Reference | |||
L2 | 6 | 17 | 0.86 (0.23-3.09) | 0.814 | ||
L3 | 17 | 23 | 1.79 (0.61-5.29) | 0.289 | ||
Upper GI locationb | ||||||
Yes | 6 | 5 | 2.60 (0.72-9.37) | 0.144 | ||
No | 24 | 52 | Reference | |||
Medication history | ||||||
5-ASA/no treatment | 3 | 15 | Reference | |||
Steroid/infliximab | 2 | 7 | 1.43 (0.19-10.58) | 0.727 | ||
AZA | 10 | 29 | 1.72 (0.41-7.23) | 0.456 | ||
Thalidomide | 15 | 6 | 12.50 (2.63-59.47) | 0.002 | 38.18 (4.18-348.14) | 0.001 |
a Defined as any surgery that comprised of a diversion, stricturoplasty, and luminal resection, anytime during the follow-up period. Perianal abscess drainage or seton placement were not included.